The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of TEV-'749 in adult patients with schizophrenia. A key secondary objective was to further evaluate the efficacy of ...

You can get in touch with Ian by emailing [email protected]. Languages: English. The new phase comes in the form of a pattern of electron spins—half of which are highly ordered, or "cold ...

Hallucinations and delusions are the most common symptoms. Psychosis can occur as part of many conditions, including schizophrenia and bipolar disorder. People with psychosis may experience ...

Two scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have discovered a new phase of matter while studying a model system of a magnetic material. The phase is a ...

9 Nintendo Switch 2 Games It NEEDS to Have - Super Mario Odyssey 2 & More! Watch on YouTube The second phase of Nintendo's game launch plan is then reportedly set for around October-November ...

Background We aimed to investigate the prodromal phase of multiple sclerosis (MS) by investigating annual sickness absence rates before MS onset. Methods A retrospective cohort study was conducted ...

In the initial phase, we had applied for a smaller downstream capacity. Currently, we have a module plant on the ground. We are confident that by December of this calendar year, we will begin ...

Researchers at Washington University in St. Louis have created a new phase of matter known as a time quasicrystal, an advanced version of time crystals, which were first discovered in 2016.

Comorbid depressive disorders confound the diagnosis and therapy of schizophrenia. Using a murine model incorporating both MK801 and chronic unpredictable mild stress exposures, we successfully ...

Without reliable biomarkers, schizophrenia is difficult to detect in its early phase. Further, there is no approved medication for prodromal schizophrenia because current antipsychotics fail to show ...

Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.